Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-04-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures, agenda items including the 2022 annual report, board and supervisory reports, financial reports, profit distribution proposals, and election of board members and supervisors. The document also contains instructions for shareholders on how to attend and vote, including proxy voting. There is no actual financial data or results presented, only the announcement and procedural details for the AGM. Therefore, this document is best classified as AGM Information (AGM-R).
2023-04-28 Chinese
内部控制审计报告
Regulatory Filings
2023-04-28 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist report by the company's board dated April 28, 2023. It does not contain financial statements or financial performance data, nor is it an announcement or presentation. It is a regulatory compliance or internal control report. Given the nature of the document, it fits best under Regulatory Filings (RNS) as it is a compliance-related internal control self-assessment report that does not fit other specific categories like Annual Report or Audit Report. The document length is 3378 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2023-04-28 Chinese
瑞康医药集团股份有限公司独立董事提名人声明-王吉法
Board/Management Information Classification · 100% confidence The document is a formal statement nominating an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. The content focuses on board/management information, specifically the nomination of a board member, rather than financial results, audit, or other report types. The document length is under 5,000 characters and is a standalone statement, not an announcement of a report publication. Therefore, it fits best under the category of Board/Management Information (MANG).
2023-04-28 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the 2022 Annual Report of 瑞康医药集团股份有限公司 (Realcan Pharmaceutical Group Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, social responsibility, and full financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial statements, management analysis, and detailed business segment information for the full fiscal year 2022 (January 1 to December 31). These characteristics align with the definition of an Annual Report (10-K). FY 2022
2023-04-28 Chinese
瑞康医药集团股份有限公司独立董事提名人声明-柳喜军
Board/Management Information Classification · 95% confidence The document is a formal statement from a nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of any meeting materials or presentations. The document is a regulatory compliance statement related to board nominations, which fits best under Board/Management Information (MANG) as it concerns the nomination of a board member.
2023-04-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.